+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?

Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?

Journal of Hepatology 56(3): 686-695

Hepatocellular cancer is a significant global health problem yet the prognosis for the majority of patients has not changed significantly over the past few decades. For patients with advanced disease, sorafenib is currently the standard of care providing a survival advantage of 2-3 months in selected patients. Cytotoxic chemotherapy has been used for over 30 years but definite evidence that it prolongs survival has been lacking. Resistance remains a significant barrier for both targeted and cytotoxic agents and an understanding of the underlying mechanisms is critical if outcomes are to be improved. Here, we summarise the past and current data that constitute the evidence base for chemotherapy in HCC, review the causes of chemoresistance and suggest strategies to overcome these barriers.

(PDF same-day service: $19.90)

Accession: 036221919

Download citation: RISBibTeXText

PMID: 21971559

DOI: 10.1016/j.jhep.2011.07.031

Related references

Challenges and opportunities in chemotherapy for hepatocellular carcinoma patients. Zhonghua Gan Zang Bing Za Zhi 14(7): 537-539, 2006

Hepatocellular carcinoma occurring after successful treatment of childhood cancer with high dose chemotherapy and radiation. Gut 54(5): 732-732, 2005

Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. Clinical Breast Cancer 8(3): 215-223, 2008

Emerging new opportunities for patients with hepatic metastases from colorectal cancer or primary hepatocellular cancer. Oncologist 6(1): 12-13, 2001

Treatment for advanced hepatocellular carcinoma by transarterial chemotherapy using reservoirs or one-shot arterial chemotherapy. Journal of ChemoTherapy 9(5): 347-351, 1997

Role of chemotherapy for advanced colorectal cancer: new opportunities. Seminars in Oncology 23(1 Suppl 3): 42-50, 1996

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69(1 Suppl): 62-79, 2007

Chemotherapy in non-small cell lung cancer: opportunities for advancement. Chinese Journal of Cancer 35(1): 56-56, 2016

Iv. Combination Of Chemotherapy And Surgery In The Treatment Of Cancer. Intra-Arterial Cancer Chemotherapy With Or Without An Isolated Extracorporeal Circuit. Acta - Unio Internationalis Contra Cancrum 20: 57-62, 1964

Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Seminars in Oncology 37(2): 89-93, 2010

Radiation and chemotherapy for hepatocellular cancer. Digestive Surgery 12(1): 73-78, 1995

Cancer chemotherapy I: hepatocellular injury. Clinics in Liver Disease 11(3): 641-62, Viii, 2007

Recent advances in understanding apoptosis: New therapeutic opportunities in cancer chemotherapy. Trends in Molecular Medicine 9(6): 251-255, June, 2003

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet. Oncology 15(11): 1269-1278, 2015